Study Tests How Weight-Loss Drug BI 456906 Affects Contraceptive Levels
A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood
Background
Many women with overweight or obesity rely on oral contraceptives for family planning, a demographic group that could significantly benefit from novel weight management therapies like BI 456906. Introducing new medications, especially those that can affect gastrointestinal motility or drug metabolism, necessitates a thorough evaluation of potential drug-drug interactions to ensure contraceptive efficacy and patient safety. This crucial Phase I study was specifically designed to address the knowledge gap regarding whether BI 456906 influences the blood levels of common oral contraceptives, thereby impacting their effectiveness.
Study Design
Population
Women with overweight or obesity who rely on oral contraceptives for family planning.
Intervention
BI 456906, dose and route not specified, duration not specified.
Outcome
The study measured whether BI 456906 influences the blood levels of common oral contraceptives.